Age‐related decline in anti‐HBV antibodies in vaccinated kidney transplant recipients

Abstract

BackgroundHepatitis B virus (HBV) vaccination is indicated for all end stage kidney disease patients, including all solid organ transplant candidates. Maintenance of adequate immunity is especially important for immunosuppressed solid organ recipients who are at increased risk for donor or community acquired HBV. The impact of age and immunosuppression on long‐term maintenance of HBV immunity postvaccination has not been fully investigated.MethodsWe performed a single‐center retrospective study of 96 kidney transplant recipients, transplanted between July 2012 and December 2020, who had Hepatitis B surface antibody (HBsAb) levels measured pretransplantation and 1‐year posttransplantation. We compared the change in HBsAb levels stratified by patient's age (<45, 45–60, and >60) and by whether or not the patient received lymphocyte depleting induction therapy.ResultsOur results demonstrate that HBsAb IgG levels vary by age group, decreased significantly at 1‐year posttransplant (p < .0001) and were significantly lower in the older cohort (p = .03). Among recipients who received rabbit anti‐thymocyte globulin induction (rATG), the log HbsAb levels were significantly lower in the older age group (2.15 in age <45, 1.75 in age 45–60 and 1.47 in age >60, p = .01). Age group (p = .004), recipient HBcAb status (p = .002), and rATG (p = .048) were independently associated with >20% reduction in log HBsAb levels posttransplant.ConclusionSignificant declines in HBsAb levels occur postkidney transplantation, especially in older individuals, thus placing exposed older kidney transplant recipients at greater risk of HBV infection and associated complications. image